Is there any clinical parameter able to predict prostate cancer after initial diagnosis of atypical small acinar proliferation?
INTRODUCTION: Tissue samples from prostate biopsy may contain atypical small acinar proliferation (ASAP): present guidelines recommend a repeat biopsy policy. This study attempted to identify clinical patterns that help predict cancer detection at second biopsy. MATERIALS AND METHODS: From 1999 to 2005, 1,274 patients underwent a prostate biopsy: in 5.9% ASAP was found, and patients underwent a second biopsy. Uni- and multivariate analysis compared the clinical patterns of cancer patients with the no cancer group at second biopsy. RESULTS: Univariate analysis showed significant differences in PSA ratio density, prostate volume, final PSA values and Delta PSA; at multivariate logistic regression analysis, only PSA ratio (OR = 0.743, 95% CI 0.620-0.891) and prostate volume (OR = 0.960, 95% CI 0.924-0.998) were predictive of malignancy. CONCLUSIONS: In our experience, PSA ratio and prostate volume seem to be independent predictors of prostate cancer at re-biopsy.(c) 2008 S. Karger AG, Bas
Related Questions
- What does it mean when my report says the findings are "atypical", "atypical small acinar proliferation (ASAP)", or "suspicious for cancer" or "glandular atypia" or "atypical glandular proliferation"?
- Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?
- Based on the clinical picture and the initial laboratory findings, what is the most likely diagnosis?
